GCAF: A Potential Drug Target Or Biomarker (G26175)

Target Name: LYSET

NCBI ID: G26175

LYSET

GCAF: A Potential Drug Target Or Biomarker

Lyset (GCAF) is a protein that is expressed in various tissues of the human body, including the brain, heart, and muscle. It is a key regulator of cell growth and differentiation, and is involved in the development and maintenance of tissues. GCAF has also been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, GCAF has generated a lot of interest as a potential drug target or biomarker.

Drug Target

GCAF has been identified as a potential drug target due to its involvement in several key signaling pathways. One of the most significant is the TGF-β pathway, which is involved in cell growth, differentiation, and survival. GCAF has been shown to play a role in regulating TGF-β activity, and has been shown to interact with several TGF-β signaling pathway proteins, including Smad2 and Add2.

Additionally, GCAF has been shown to be involved in the FGF signaling pathway, which is involved in cell growth and development. The FGF pathway is a critical regulator of tissue growth and development, and has been implicated in a variety of diseases, including cancer. GCAF has been shown to play a role in regulating FGF activity, and has been shown to interact with several FGF signaling pathway proteins, including Fgfr1.

Biomarker

GCAF has also been identified as a potential biomarker for a variety of diseases, including cancer. GCAF has been shown to have altered levels in a variety of cancer types, and has been shown to be involved in the development and progression of cancer. For example, studies have shown that GCAF levels are elevated in breast cancer, and that these levels are associated with poor prognosis. Additionally, GCAF has been shown to be involved in the development of neurodegenerative diseases, and has been shown to be involved in the progression of these diseases.

Conclusion

GCAF is a protein that is expressed in various tissues of the human body, and has been shown to play a role in several key signaling pathways. As a result, GCAF has generated a lot of interest as a potential drug target or biomarker. Further research is needed to fully understand the role of GCAF in these processes, and to determine its potential as a drug or biomarker.

Protein Name: Lysosomal Enzyme Trafficking Factor

Functions: Required for mannose-6-phosphate-dependent trafficking of lysosomal enzymes (PubMed:36074822, PubMed:36096887, PubMed:36074821). LYSET bridges GlcNAc-1-phosphate transferase (GNPTAB), to the membrane-bound transcription factor site-1 protease (MBTPS1), thus allowing proteolytic activation of the GNPTAB. GNPTAB is involved in the regulation of M6P-dependent Golgi-to-lysosome trafficking of lysosomal enzymes (PubMed:36096887, PubMed:36074822, PubMed:36074821). LYSET is thus an essential factor for maturation and delivery of lysosomal hydrolases (PubMed:36074822)

The "LYSET Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LYSET comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets